Mutation Rate of AmpC β-Lactamase-Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38527853.
- Also identified by DOI 10.1093/cid/ciae160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase-producing Enterobacterales, species with low in vitro mutation rates for AmpC derepression were associated with fewer treatment failures due to AmpC overproduction (adjusted hazard ratio, 0.5 [95% CI, .2-.9]). However, compared to cefepime/carbapenems, using third-generation cephalosporins as definitive therapy remained associated with this adverse outcome (15% vs 1%).
Medical subject headings
- beta-Lactamases
- Bacterial Proteins
- Anti-Bacterial Agents
- Enterobacteriaceae
- Enterobacteriaceae Infections
- Mutation Rate